|
28 Jun 2020 |
Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile
|
|
28 Jun 2020 |
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
|
|
28 Jun 2020 |
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
|
|
26 Jun 2020 |
Department of Defense Awards Ology Bioservices Contract to Advance Anti-Botulinum Neurotoxin Monoclonal Antibodies
|
|
26 Jun 2020 |
Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer
|
|
26 Jun 2020 |
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers
|
|
25 Jun 2020 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
|
|
24 Jun 2020 |
Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients
|
|
24 Jun 2020 |
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
|
|
24 Jun 2020 |
Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint
|
|
24 Jun 2020 |
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy
|
|
23 Jun 2020 |
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
|
|
23 Jun 2020 |
Teos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
|
|
23 Jun 2020 |
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
|
|
23 Jun 2020 |
HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting II
|
|
23 Jun 2020 |
F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting
|
|
23 Jun 2020 |
BioInvent enrolls first patient in Phase I/IIa trial of BI-1206 in combination with KEYTRUDA[®] for the treatment of patients with solid tumors
|
|
23 Jun 2020 |
BioInvent presents proof-of-concept data for two TNFR2-targeting antibodies
|
|
23 Jun 2020 |
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK® Platform, at AACR Virtual Annual Meeting II
|
|
23 Jun 2020 |
Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35
|
|
23 Jun 2020 |
European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
|
|
22 Jun 2020 |
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting
|
|
22 Jun 2020 |
EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II
|
|
22 Jun 2020 |
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
|
|
22 Jun 2020 |
ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
|
